We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you can join in the conversations too.
Did you know that our new General Manager, Europe, Dr. Frank Horling, was a client of BioAgilytix before joining our team? We asked him to share his perspectives on what it was like to be a BioAgilytix customer as well as what motivated him to join our lab in Hamburg, Germany.
As COVID-19 lockdowns begin to lift, the question is: where do we go from here? BioAgilytix is in a highly unique position to help both biopharma & companies with testing to keep their work on track: whether that means progressing clinical trials or reopening their businesses and offices safely.
Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.
A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the promising results.
BioAgilytix's Regan Reynolds shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS is diagnosed and treated in the USA.
As the pharma & biotech industry is working around the clock to address the unprecedented COVID-19 health crisis, they are also giving the world hope that we will overcome these trying times. We highlight some of the important solutions in development & why we're all pushing forward: because to create new breakthroughs, you can't stop science.
New data suggests Cytokine Release Syndrome in patients with severe cases of COVID-19 may cause death. See how BioAgilytix can apply our validated MSD cytokine/chemokine panels to support cytokine monitoring in COVID-19 vaccine & therapeutic programs.
When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable of handling quick turnarounds and rescue projects. We look at an example of how BioAgilytix sprung to action to transform a troubled study.
On May 7, we'll be hosting webinar highlighting the importance of streamlining the time & cost of bioanalytical testing to support therapeutic development for viral infections such as COVID19 and influenza. We share a sneak peek of the content here.
Services
Platforms